Type 2 Diabetes Mellitus Clinical Trial
Official title:
Evaluation of Iphone Technology in Diabetes Treatment
Background
With the emergence of the internet, health care professionals are changing the way they
approach diabetes management. Internet Blood Glucose Monitoring Systems (IBGMS) are aimed at
keeping blood glucose levels normal or in the range of acceptable levels to prevent the
complications associated with diabetes. The Principal Investigators have completed a
randomized clinical trial supporting the efficacy of IBGMS (1,2).
Patient satisfaction of reporting platform is essential to encourage patient reporting and
participation in IBGMS. In this study, we wish to compare two different types of meters
which will be used to internet blood glucose monitoring: the BG Star Meter (Conventional
Meter), and the iBG Star Group (iPhone Technology).
Purpose and Rationale
Patients who are more satisfied with their meter and internet reporting platform are more
likely to participate in an internet monitoring system. Patients often lack the motivation
to report to their endocrinologist. With increased reporting to their healthcare
professional, patients are more likely to benefit from such a system. This study aims to
compare two types of meters and their respective internet reporting platforms to encourage
patient participation.
Objectives
Our main goal is to compare the two types of meters.
Primary Outcomes Include:
1. Patient Satisfaction as measured by the "Diabetes Treatment Satisfaction Questionnaire"
(DTSQ)
2. Frequency of reporting to endocrinologist
3. Number of Self-Monitoring Blood Glucose (SMBG) tests
4. Time taken to teach each patient the platforms
Research Design/Methods
Sample Size: 50 patients will be randomized into two groups:
BG Star Group (Conventional Meter) 25 patients will use the (conventional) BG star meter in
which patients will upload their readings onto a computer and send in their readings via
email.
IBG Star Group (iPhone Technology) 25 patients will be randomized to the iBGstar system will
upload their readings to their iPhone and send in their readings using the iPhone.
Patients will be recruited from a Physician's private office.
Both the (Conventional meter) BG star and iBG star (iPhone Technology) group will be asked
to perform SMBG 3 or more times per day and to upload their metered glucose values online
every 2 weeks to be reviewed by the doctor.
Inclusion criteria:
- Type 1s
- Type 2s, can be on insulin, oral antihyperglycemic agents, or in combination.
- Willingness to test blood glucose levels a minimum of 3 times daily
- Willingness to be randomized
- Trained in self-blood glucose monitoring
- Internet Access
Exclusion criteria: Patients who do not meet the above criteria or are not willing to
participate will not be included in the study.
Background/Hypothesis
Management of diabetes is an evolving challenge to health care professionals. The
fluctuations of glucose levels over the lifetime of patients with diabetes can lead to
complications such as nephropathy, neuropathy, retinopathy and cardiovascular diseases.
Although diabetes is a chronic disease, it can be controlled with use of medications (oral
agents or insulin), and/or changes in life-style and diet.
With the emergence of the internet, health care professionals are changing the way they
approach diabetes management. Internet Blood Glucose Monitoring Systems (IBGMS) are aimed at
keeping blood glucose levels normal or in the range of acceptable levels to prevent the
complications associated with diabetes. The Principal Investigators have completed a
randomized clinical trial supporting the efficacy of IBGMS (1,2).
Patient satisfaction of reporting platform is essential to patient reporting and
participation in IBGMS. In this study, we wish to compare two different types of meters
which will be used to internet blood glucose monitoring: the BG Star Meter (Conventional
Meter), and the iBG Star Group (iPhone Technology).
Purpose and Rationale
Patients who are more satisfied with their meter and internet reporting platform are more
likely to participate in an internet monitoring system. Patients often lack the motivation
to report to their endocrinologist. With increased reporting to their healthcare
professional, patients are more likely to benefit from such a system. This study aims to
compare two types of meters and their respective internet reporting platforms to encourage
patient participation.
Objectives
Our main goal is to compare the two types of meters.
Primary Outcomes Include:
1. Patient Satisfaction as measured by the "Diabetes Treatment Satisfaction Questionnaire"
(DTSQ)
2. Frequency of reporting to endocrinologist
3. Number of Self-Monitoring Blood Glucose (SMBG) tests
4. Time taken to teach each patient the platforms
Research Design/Methods
Sample Size: 50 patients will be randomized into two groups:
BG Star Group (Conventional Meter) 25 patients will use the (conventional) BG star meter in
which patients will upload their readings onto a computer and send in their readings via
email.
IBG Star Group (iPhone Technology) 25 patients will be randomized to the iBGstar system will
upload their readings to their iPhone and send in their readings using the iPhone.
Patients will be recruited from a Physician's private office.
Both the (Conventional meter) BG star and iBG star (iPhone Technology) group will be asked
to perform SMBG 3 or more times per day and to upload their metered glucose values online
every 2 weeks to be reviewed by the doctor.
Inclusion criteria:
- Type 1s
- Type 2s, can be on insulin, oral antihyperglycemic agents, or in combination.
- Willingness to test blood glucose levels a minimum of 3 times daily
- Willingness to be randomized
- Trained in self-blood glucose monitoring
- Internet Access
Exclusion criteria: Patients who do not meet the above criteria or are not willing to
participate will not be included in the study.
Confidentiality According to the guidelines of the University of British Columbia
(UBC)/Providence Health Care Research Ethics Boards, the identity of participants will be
kept confidential.
Data for each patient will be collected from the Clinical Research Coordinator and the
Internet based glucose monitoring system. These data will only be accessed by the
investigators and will be inputted into an Excel® spreadsheet where each patient will be
given a unique identifier. All data pertaining to individual patients will be kept locked in
the office of the study investigators.
Calculations and Statistics Statistical analysis will be performed on site by the
researchers. Each group will complete the DTSQ. Questions revolve around satisfaction of
treatment and are to be answered on a scale of 1 (very dissatisfied) to 6 (very Satisfied).
Frequency of reporting will be determined through number of reports sent in per month. Total
strip count will be recorded for each group. Time will be measured for the time it takes to
train each patient in their respective meter/platform. All outcome measurements will be
analysed using independent samples t-tests. Participants will only be identified by coded
initials and a number to protect privacy.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
| Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
| Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
| Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
| Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
| Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
| Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
| Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
| Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
| Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
| Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
| Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |